This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1076029609349500v1 15/6/609    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Stein, P. D. Articles by Yaekoub, A. Y. PubMed PubMed Citation Articles by Stein, P. D. Articles by Yaekoub, A. Y. Social Bookmarking                         What's this?

Anticoagulants for Acute Venous Thromboembolism: What We Think We Know and What the Data Show for Timing of Recurrent Events

^* To whom correspondence should be addressed. E-mail: steinp{at}trinity-health.org.

	Abstract

Although heparin is administered to prevent early recurrences of venous thromboembolism (VTE) by preventing new thrombi, allowing old thrombi to attach to venous walls, and covering warfarin until it is therapeutic, heparin largely prevents late recurrences of VTE (after 5 days). The dreaded early occurrence of pulmonary embolism (PE) (on or before day 5) while waiting for the vitamin K antagonist to become antithrombotic did not occur among patients with deep venous thrombosis (DVT), who received acencoumarol alone. Fewer total recurrences resulted if a therapeutic level of heparin was reached within the first 24 hours of treatment of DVT. Fewer total recurrences also resulted if heparin was consistently maintained at therapeutic levels. A recurrent VTE within 5 days, however, occurred infrequently in those in whom heparin was not given, or therapeutic levels were delayed or not maintained. The incidence of early recurrent VTE was not lower in those who received adequate heparin than in those who did not, although the data are sparse. The true incidence of early recurrent VTE is uncertain due to the broad confidence intervals for the observed frequency of early recurrent events. Later recurrences are the norm and may be reduced by early treatment with adequate heparin.

First published on October 13, 2009, doi:10.1177/1076029609349500

Clinical and Applied Thrombosis/Hemostasis 2009;15:609.

A more recent version of this article appeared on December 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?